Literature DB >> 7680588

Managing chronic hepatitis C virus infection.

J Y Lau, G L Davis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680588      PMCID: PMC1676809          DOI: 10.1136/bmj.306.6876.469

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  10 in total

1.  Effect of interferon-alpha 2b on cryoglobulinemia related to hepatitis C virus infection.

Authors:  J M Durand; G Kaplanski; P Lefevre; M A Richard; L Andrac; C Trepo; J Soubeyrand
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

2.  Measurement of anti-GOR antibodies in prevention of post-transfusion non-A, non-B hepatitis.

Authors:  H Yoshizawa; N Nojiri; K Takahashi
Journal:  Lancet       Date:  1991-01-05       Impact factor: 79.321

3.  A long-term study of hepatitis C virus replication in non-A, non-B hepatitis.

Authors:  P Farci; H J Alter; D Wong; R H Miller; J W Shih; B Jett; R H Purcell
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

4.  Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials.

Authors:  F Tinè; S Magrin; A Craxì; L Pagliaro
Journal:  J Hepatol       Date:  1991-09       Impact factor: 25.083

5.  Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma.

Authors:  M Colombo; G Kuo; Q L Choo; M F Donato; E Del Ninno; M A Tommasini; N Dioguardi; M Houghton
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

6.  Ribavirin treatment for chronic hepatitis C.

Authors:  O Reichard; J Andersson; R Schvarcz; O Weiland
Journal:  Lancet       Date:  1991-05-04       Impact factor: 79.321

7.  Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay.

Authors:  C L Van der Poel; H T Cuypers; H W Reesink; A J Weiner; S Quan; R Di Nello; J J Van Boven; I Winkel; D Mulder-Folkerts; P J Exel-Oehlers
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

8.  Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV.

Authors:  A Alberti; G Morsica; L Chemello; D Cavalletto; F Noventa; P Pontisso; A Ruol
Journal:  Lancet       Date:  1992-09-19       Impact factor: 79.321

9.  Improved serodiagnosis of posttransfusion hepatitis C virus infection by a second-generation immunoassay based on multiple recombinant antigens.

Authors:  J T Wang; T H Wang; J T Lin; J C Sheu; C Z Lee; D S Chen
Journal:  Vox Sang       Date:  1992       Impact factor: 2.144

10.  Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comité des Anti-Viraux.

Authors:  N Boyer; P Marcellin; C Degott; F Degos; A G Saimot; S Erlinger; J P Benhamou
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

  10 in total
  4 in total

1.  Interferon first in chronic hepatitis C.

Authors:  M Goggins; A Tobin
Journal:  BMJ       Date:  1993-05-01

2.  Lymphoblastoid interferon alfa treatment in chronic hepatitis C.

Authors:  R Iorio; P Pensati; S Porzio; I Fariello; S Guida; A Vegnente
Journal:  Arch Dis Child       Date:  1996-02       Impact factor: 3.791

3.  Polymyositis and dermatomyositis: no persistence of enterovirus or encephalomyocarditis virus RNA in muscle.

Authors:  P J Jongen; G J Zoll; M Beaumont; W J Melchers; L B van de Putte; J M Galama
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

4.  Hepatitis C infection among injecting drug users attending the National Drug Treatment Centre.

Authors:  R Smyth; E Keenan; A Dorman; J O'Connor
Journal:  Ir J Med Sci       Date:  1995 Oct-Dec       Impact factor: 1.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.